Ovarian Cancer Immunotherapy and Personalized Medicine

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jul 2

PMID 34207103

Citations 152

Authors

Susan Morand

Monika Devanaboyina

Hannah Staats

Laura Stanbery

John Nemunaitis

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer response to immunotherapy is limited; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. These markers include tumor mutation burden, PD-L1, tumor-infiltrating lymphocytes, homologous recombination deficiency, and neoantigen intratumoral heterogeneity. Future directions in the treatment of ovarian cancer include the utilization of these biomarkers to select ideal candidates. This paper reviews the role of immunotherapy in ovarian cancer as well as novel therapeutics and study designs involving tumor biomarkers that increase the likelihood of success with immunotherapy in ovarian cancer.

Citing Articles

Unlocking the future: mitochondrial genes and neural networks in predicting ovarian cancer prognosis and immunotherapy response.

Tang Z, Pan Y, Li W, Ma R, Wang J Transl Cancer Res. 2025; 14(1):512-521.

PMID: 39974375 PMC: 11833377. DOI: 10.21037/tcr-24-1233.

The role of MUC16 in tumor biology and tumor immunology in ovarian cancer.

Yang N, Zhou X, Gong Y, Deng Z BMC Cancer. 2025; 25(1):294.

PMID: 39972413 PMC: 11837316. DOI: 10.1186/s12885-025-13461-0.

Pregnancy is associated with the prognosis of ovarian cancer patients with abdominal metastasis.

Cui H, Zhu Q, Zhao H, Liu H, Wang N Am J Cancer Res. 2025; 15(1):168-181.

PMID: 39949936 PMC: 11815367. DOI: 10.62347/JUJQ9225.

Integrative prognostic modeling of ovarian cancer: incorporating genetic, clinical, and immunological markers.

Lin A, Xue F, Pan C, Li L Discov Oncol. 2025; 16(1):115.

PMID: 39900707 PMC: 11790546. DOI: 10.1007/s12672-025-01819-6.

Sempervirine inhibits proliferation, invasion and metastasis of ovarian cancer cells and induces ultrastructural changes in vivo.

Chen D, Tan Y, Chen T, Wang Q, Yan Y, Zhao X J Ovarian Res. 2025; 18(1):17.

PMID: 39875926 PMC: 11773766. DOI: 10.1186/s13048-024-01580-4.

References

Shen T, Pajaro-Van de Stadt S, Yeat N, Lin J . Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. Front Genet. 2015; 6:215. PMC: 4469892. DOI: 10.3389/fgene.2015.00215. View

Collins F, Morgan M, Patrinos A . The Human Genome Project: lessons from large-scale biology. Science. 2003; 300(5617):286-90. DOI: 10.1126/science.1084564. View

Walters C, Arend R, Armstrong D, Naumann R, Alvarez R . Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol Oncol. 2013; 131(2):493-8. DOI: 10.1016/j.ygyno.2013.07.080. View

Kim D, Kim J, Kim Y, Kim J, Ioannides C . The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor. Yonsei Med J. 2002; 43(6):691-700. DOI: 10.3349/ymj.2002.43.6.691. View

Matulonis U, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I . Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019; 30(7):1080-1087. DOI: 10.1093/annonc/mdz135. View

Riester M, Wei W, Waldron L, Culhane A, Trippa L, Oliva E . Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014; 106(5). PMC: 4580556. DOI: 10.1093/jnci/dju048. View

Zhu J, Wen H, Bi R, Wu Y, Wu X . Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol. 2017; 28(6):e77. PMC: 5641527. DOI: 10.3802/jgo.2017.28.e77. View

Assaraf Y, Leamon C, Reddy J . The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat. 2014; 17(4-6):89-95. DOI: 10.1016/j.drup.2014.10.002. View

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

10.

Moore K, Martin L, OMalley D, Matulonis U, Konner J, Perez R . Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2016; 35(10):1112-1118. PMC: 5559878. DOI: 10.1200/JCO.2016.69.9538. View

11.

Diaz Jr L, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022; 23(5):659-670. PMC: 9533375. DOI: 10.1016/S1470-2045(22)00197-8. View

12.

Sakellariou-Thompson D, Forget M, Creasy C, Bernard V, Zhao L, Kim Y . 4-1BB Agonist Focuses CD8 Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clin Cancer Res. 2017; 23(23):7263-7275. PMC: 6097625. DOI: 10.1158/1078-0432.CCR-17-0831. View

13.

Tanyi J, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R . Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018; 10(436). DOI: 10.1126/scitranslmed.aao5931. View

14.

Lee J, Yi J, Kim H, Lim J, Kim S, Nam B . An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION. Jpn J Clin Oncol. 2019; 49(8):789-792. DOI: 10.1093/jjco/hyz085. View

15.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

16.

Kalli K, Block M, Kasi P, Erskine C, Hobday T, Dietz A . Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res. 2018; 24(13):3014-3025. PMC: 6030477. DOI: 10.1158/1078-0432.CCR-17-2499. View

17.

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W . Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6):307-325. DOI: 10.1038/s41568-019-0144-6. View

18.

Park J, Lee J, Kim S . How to use immune checkpoint inhibitor in ovarian cancer?. J Gynecol Oncol. 2019; 30(5):e105. PMC: 6658602. DOI: 10.3802/jgo.2019.30.e105. View

19.

Morse C, Elvin J, Gay L, Liao J . Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. Gynecol Oncol Rep. 2017; 21:78-80. PMC: 5510487. DOI: 10.1016/j.gore.2017.06.013. View

20.

Lee N, Zakka L, Mihm Jr M, Schatton T . Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016; 48(2):177-87. DOI: 10.1016/j.pathol.2015.12.006. View